DHS Working Papers No. 125
WHO/CDS/TB/99.272
Distr.: General, Original: French
J Epidemiol Infect Dis 1(1): 00003.n DOI: 10.15406/jeid.2017.01.00003
Published: September 14, 2017
This paper presents lessons learned from previous flood responses in developing countries, based on a structured review of the literature. It is intended for people working in relief and recovery operations who have to decide if, when and how to intervene after a flood.
Research Article
Received: August 21, 2017; Accepted: August 29, 2017; Published: Spetember 05,
2017
This article is available in: http://www.imedpub.com/advanced-techniques-in-clinical-microbiology/
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
DHS Working Papers No. 113
Petersen et al. Int J Ment Health Syst (2016) 10:30 DOI 10.1186/s13033-016-0060-z
Accessed on 13.02.2020
Il est habituel de penser le handicap comme une perte d'autonomie et le handicapé dans une situation de dépendance sociale(1). Au cours d'une enquête menée en 1985 et 1986 au Sénégal sur les solidarités en milieu urbain, j'ai été amené à m'interroger sur ce qu'on... appelle volontiers "la prise en charge sociale du handicap"(2) et. à la lumière des données empiriques recueillies, à proposer une autre lecture des rapports sociaux en jeu autour de l'infirmité physique(3). Ainsi, parti sur le terrain avec l'idée d'étudier comment la famille et la société africaines venaient en aide à leurs handicapés, j'ai découvert que le handicapé pouvait aussi bien à son tour aider ses parents et son groupe. Plus encore, m'intéressant initialement aux conséquences socio-professionnelles du handicap, j'ai dû introduire secondairement d'autres dimensions de l'échange social, en particulier les relations matrimoniales, de façon à rendre compte plus complètement de la signification sociale du handicap.
more
L’utilisation excessive ou inadaptée des antibiotiques chez l’homme et chez l’animal contribue à amplifier la menace provenant de la résistance à ces produits. Certains types de bactéries susceptibles de provoquer des infections graves chez les humains sont déjà devenus ... résistants à la plupart des traitements disponibles et très peu d’options prometteuses sont actuellement en cours de développement pour prendre le relais
more
December 2015
National guidelines for of Clubfoot
BMC Health Services Research (2019) 19:458 https://doi.org/10.1186/s12913-019-4315-7
Global Qualitative Nursing Research March 31, 2021 Research Article Find in PubMed
https://doi.org/10.1177/23333936211005475
Preventing tuberculosis infection from progressing to tuberculosis disease is a crucial component of the goal to eliminate tuberculosis. When deciding on the use of tuberculosis preventive therapy among household contacts, policy makers regularly ask questions, such as whether tuberculosis preventiv...e therapy is effective, safe, and feasible in a programme setting and what it will cost. For contact management and tuberculosis preventive therapy for multidrug-resistant and rifampicin-resistant tuberculosis, studies from high-income and low-income countries have shown feasibility, safety, and effectiveness.
However, there is scarce information on the cost of tuberculosis preventive therapy for multidrug-resistant and rifampicin-resistant tuberculosis. In The Lancet Global Health, Peter Dodd and colleagues show that household contact management strategies are cost-effective even in low-income and middle-income countries, which has important policy implications for achieving the END TB Strategy goals.
more
Background
Access to medicines is important for long‐term care of cardiovascular diseases and hypertension. This study provides a cross‐country assessment of availability, prices, and affordability of cardiovascular disease and hypertension medicines to identify areas for improvement in access ...to medication treatment.
Methods and Results
We used the World Health Organization online repository of national essential medicines lists (EMLs) for 53 countries to transcribe the information on the inclusion of 12 cardiovascular disease/hypertension medications within each country's essential medicines list. Data on availability, price, and affordability were obtained from 84 surveys in 59 countries that used the World Health Organization's Health Action International survey methodology. We summarized and compared the indicators across lowest‐price generic and originator brand medicines in the public and private sectors and by country income groups. The average availability of the select medications was 54% in low‐ and lower‐middle‐income countries and 60% in high‐ and upper‐middle‐income countries, and was higher for generic (61%) than brand medicines (41%). The average patient median price ratio was 80.3 for brand and 16.7 for generic medicines and was higher for patients in low‐ and lower‐middle‐income countries compared with high‐ and upper‐middle‐income countries across all medicine categories. The costs of 1 month's antihypertensive medications were, on average, 6.0 days’ wage for brand medicine and 1.8 days’ wage for generics. Affordability was lower in low‐ and lower‐middle‐income countries than high‐ and upper‐middle‐income countries for both brand and generic medications.
Conclusions
The availability and accessibility of pharmaceuticals is an ongoing challenge for health systems. Low availability and high costs are major barriers to the use of and adherence to essential cardiovascular disease and antihypertensive medications worldwide, particularly in low‐ and lower‐middle‐income countries.
more
Heart failure (HF) is a leading global public health problem with >64 million prevalent cases globally. Patients with HF with reduced ejection fraction (HFrEF) from low- and middle-income countries experience a 22% to 58% higher 1-year mortality rate than those in high-income countries.1 Guideline-d...irected medical therapy (GDMT) consisting of ACE (angiotensin-converting enzyme) inhibitors or ARB (angiotensin receptor blockers) or ARNI (angiotensin receptor-neprilysin inhibitors), β-blockers, MRA (mineralocorticoid receptor antagonists), and SGLT2 (sodium-glucose cotransporter 2) inhibitors substantially reduces mortality among patients with HFrEF. These medicines are among the most cost-effective interventions and are thus included as the highest priority health system interventions recommended by the Disease Control Priorities Project.2 Despite this high-quality evidence, GDMT remains widely underutilized in low- and middle-income countries resulting in widespread undertreatment of patients with HFrEF due to health system-, provider-, and patient-level barriers.1 National essential medicines lists (EMLs) promoted by the World Health Organization (WHO) guide countries on which medications to purchase in the setting of limited resources and have resulted in higher procurement and availability of essential medicines in the public sector.3 We provide a cross-sectional analysis of national EMLs in 53 low- and middle-income countries, and availability, price, and affordability of GDMT in select countries to identify potential barriers to access to these essential medicines for patients with HFrEF.
more
The document "Diabetes and Ramadan: Practical Guidelines 2021," published by Elsevier, provides updated guidance for managing diabetes during Ramadan fasting. Developed by the International Diabetes Federation (IDF) and the Diabetes and Ramadan (DAR) International Alliance, the guidelines address ke...y aspects for individuals with diabetes who choose to fast, including risk assessment, blood glucose monitoring, insulin and medication adjustments, and the management of special populations (such as pregnant women, the elderly, and those with chronic conditions). Emphasis is placed on individualized patient education before Ramadan to ensure safe fasting practices and minimize risks like hypoglycemia and hyperglycemia.
more